Literature DB >> 34140100

Glucose Homeostasis, Hypoglycemia, and the Burnt-Out Diabetes Phenomenon in Kidney Disease.

Connie M Rhee1, Csaba P Kovesdy2, Kamyar Kalantar-Zadeh3.   

Abstract

Chronic kidney disease (CKD) is among the most prevalent and dire complications of diabetes mellitus in adults across the world. Diabetes substantially contributes to the burden of kidney disease, such that one third to one half of CKD in the United States and many other countries is attributable to diabetic kidney disease (DKD). As DKD progresses to end-stage renal disease (ESRD), patients are at heightened risk for atypical glycemic complications, including the development of burnt-out diabetes, manifested by hypoglycemic bouts and poor outcomes. Furthermore, even in the absence of diabetes, hypoglycemia is a frequent occurrence in CKD patients that may contribute to their high burden of cardiovascular disease and death. Extrapolation of data from clinical trials in high-cardiovascular-risk populations and observational studies in patients with non-dialysis-dependent (NDD) CKD and ESRD suggest that moderate glycemic targets defined by glycated hemoglobin levels of 6% to 8% and glucose levels of 100 to 150 mg/dL are associated with better survival in DKD patients. However, given the imprecision of glycated hemoglobin levels in kidney disease, further research is needed to determine the optimal glycemic metric and target in diabetic NDD-CKD and ESRD patients. Given their exceedingly high cardiovascular morbidity and mortality, there is a compelling need for further investigation of how to optimally manage dysglycemia in the NDD-CKD and ESRD populations.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34140100      PMCID: PMC8221113          DOI: 10.1016/j.semnephrol.2021.03.004

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  50 in total

Review 1.  Transition of care from pre-dialysis prelude to renal replacement therapy: the blueprints of emerging research in advanced chronic kidney disease.

Authors:  Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Elani Streja; Connie M Rhee; Melissa Soohoo; Joline L T Chen; Miklos Z Molnar; Yoshitsugu Obi; Daniel Gillen; Danh V Nguyen; Keith C Norris; John J Sim; Steve S Jacobsen
Journal:  Nephrol Dial Transplant       Date:  2017-04-01       Impact factor: 5.992

2.  1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia.

Authors:  R H Mak
Journal:  Kidney Int       Date:  1998-05       Impact factor: 10.612

Review 3.  Glycemic control and burnt-out diabetes in ESRD.

Authors:  Csaba P Kovesdy; Jong C Park; Kamyar Kalantar-Zadeh
Journal:  Semin Dial       Date:  2010-03-30       Impact factor: 3.455

4.  KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.

Authors: 
Journal:  Am J Kidney Dis       Date:  2012-11       Impact factor: 8.860

5.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

6.  Increased risk of stroke in patients with chronic kidney disease after recurrent hypoglycemia.

Authors:  Tung-Min Yu; Cheng-Li Lin; Shih-Ni Chang; Fung-Chang Sung; Chia-Hung Kao
Journal:  Neurology       Date:  2014-07-16       Impact factor: 9.910

7.  Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients.

Authors:  R H Mak
Journal:  Kidney Int       Date:  1992-04       Impact factor: 10.612

8.  Characterization and partial purification of a factor from uremic human serum that induces insulin resistance.

Authors:  M L McCaleb; M S Izzo; D H Lockwood
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

9.  Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?

Authors:  Jane E B Reusch
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

10.  Diabetic kidney disease: a report from an ADA Consensus Conference.

Authors:  Katherine R Tuttle; George L Bakris; Rudolf W Bilous; Jane L Chiang; Ian H de Boer; Jordi Goldstein-Fuchs; Irl B Hirsch; Kamyar Kalantar-Zadeh; Andrew S Narva; Sankar D Navaneethan; Joshua J Neumiller; Uptal D Patel; Robert E Ratner; Adam T Whaley-Connell; Mark E Molitch
Journal:  Diabetes Care       Date:  2014-10       Impact factor: 19.112

View more
  2 in total

Review 1.  Novel approaches to hypoglycemia and burnt-out diabetes in chronic kidney disease.

Authors:  Connie M Rhee; Kamyar Kalantar-Zadeh; Katherine R Tuttle
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-01-01       Impact factor: 2.894

Review 2.  Prevalence of Sarcopenia and Its Impact on Cardiovascular Events and Mortality among Dialysis Patients: A Systematic Review and Meta-Analysis.

Authors:  Wannasit Wathanavasin; Athiphat Banjongjit; Yingyos Avihingsanon; Kearkiat Praditpornsilpa; Kriang Tungsanga; Somchai Eiam-Ong; Paweena Susantitaphong
Journal:  Nutrients       Date:  2022-09-30       Impact factor: 6.706

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.